Announcement on Carrying Out Foreign Exchange Derivative Transactions for Hedging Purposes
The company and its board of directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
Key Content Notice:
-
To reduce foreign exchange risk and enhance financial stability, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") plans to conduct foreign exchange derivative transactions totaling up to USD 550 million (or equivalent in foreign currency) for hedging purposes. These transactions will be valid for 12 months from the date of approval by the Company's shareholders' meeting. The aforementioned quota can be used on a revolving basis within the approval period. During the validity period, the Company and its consolidated subsidiaries will conduct foreign exchange derivative transactions, with the outstanding balance at any point in time not exceeding USD 550 million (or equivalent in foreign currency) (including amounts related to the reinvestment of profits from the aforementioned transactions). The upper limit of the transaction margin and premium (including the value of collateral provided for the transactions, the credit line expected to be used from financial institutions, and the margin reserved for contingency measures, etc.) is expected to not exceed USD 55 million (or equivalent in foreign currency). If the term of any single transaction exceeds the authorization period, the authorization period will be automatically extended until the termination of that transaction. The transaction types include forwards, swaps, options, and related combination products. The Company's foreign exchange derivative transactions will be handled by financial institutions approved by the State Administration of Foreign Exchange and the People's Bank of China, which possess operating qualifications.
-
This matter has been reviewed and approved by the 20th meeting of the 6th Board of Directors held on March 30, 2026, and is subject to approval by the shareholders' meeting.
-
Risk Warning: The foreign exchange derivative transactions planned by the Company will adhere to the principles of legality, prudence, safety, and effectiveness. Speculative or arbitrage trading operations will not be undertaken. However, there are certain market risks, liquidity risks, and performance risks during the transaction process. Investors are kindly requested to pay attention to investment risks.